Hopefully the start of human trials puts this drug development opportunity back onto the radar of investors.
from memory, this is a drug that (if successful through trials) has the potential to generate profits of $10 billion per year by 2030
Compare that with CSL … one of Australia’s biggest companies, yet making profits a fraction of that.
i suspect this is the drug that the US investors would be most interested in getting behind
Ann: Approval to Commence Human Trials in Kidney Program, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.020(1.72%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| $1.19 | $1.20 | $1.18 | $66.67K | 56.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18415 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 684 | 3 |
View Market Depth
| Last trade - 12.22pm 17/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |